03:30pm Chair Introduction

Troels Jordansen, Chief Executive Officer, Glycostem Therapeutics

03:35pm Presentation: Cell and Gene Therapy: These Identifiers Are Getting Out of Hand (Virtual)

• How it started: a brief overview of how we got here and why there are so many different Cell and Gene Therapy product identifiers
• How’s it going: ISBT-128 ST-028 (Chain of Identity Identifier) and benefits to clinical site & patient
• Next Steps

Beth Gardner, Senior Director, Patient Supply, Beam Therapeutics

03:50pm Presentation: Key Considerations When Choosing Recombinant Proteins for Cell and Gene Therapy Applications

• Interleukins (ILs): The role they play in the regulation of adaptive cellular response
• Critical factors when selecting a supplier for your recombinant proteins
• Developing recombinant growth factors and cytokines for cell-based therapies
• Achieving optimal results through a scientifically-driven selection of products
• Why a close partnership with your supplier can accelerate the development process to therapy 

Robert Newman, Chief Scientific Officer, FujiFilm Irvine Scientific

04:05pm Presentation: Advancements in Patient Access for Cell Therapies

• Types of Allogeneic Cell Therapies
• Benefits of the Luminary Method
• Solving the 11 day to 21 day wait period for current autologous therapies
  • In-house product at key Cancer Centers (readily available)
  • Overnight shipment to domestic locations
  • Two-Day shipments to international locations
  • Government Programs in underdeveloped nations where distribution centers could be stocked

Jeff Liter, Chief Executive Officer, Luminary Therapeutics

04:20pm Presentation: Gene Therapy — Reaching Patients at Sufficient Scale

Amy DuRoss, President, Cell and Gene Therapy, CSafe

04:35pm Closing Panel with Q&A

With all session participants Joined by: 

Lisa McClain-Moss, Vice President of Manufacturing, Longeveron